Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020 Report

“Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020” Report Highlights:

* Introduction & Classification of Peptide Vaccines
* Designing & Production of Peptide Vaccine
* Mechanism of Peptide Vaccine
* Cancer Immunotherapy with Peptide Vaccine
* Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
* Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
* Majority vaccines in Preclinical Phase: 28 Vaccines
* Global Peptide Vaccine Market Future Prospects

Download Report Sample Weblink:

https://www.kuickresearch.com/report-Global-Peptide-Vaccine-Market-&-Clinical-Pipeline-Outlook-2020.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines

1.1 Introduction

1.2 Glimpse of Antiquity



2. Need of Peptide Vaccines

2.1 Why Peptides – More Desirable

2.2 Peptide Vaccines V/S Traditional Vaccines



3. Classification of Peptide Vaccines

3.1 On the Basis of Sources Obtained

3.2 On the Basis of Length

3.3 On the Basis of Epitopes



4. Designing & Production of Peptide Vaccine

4.1 Synthetic Peptide Vaccine

4.2 Selection of Peptide Antigen

4.3 Construction of Peptide Antigen

4.4 Chemical Synthesis of Peptide Vaccine

4.4.1 Solution Phase Synthesis (SPS)

4.4.2 Solid Phase Peptide Synthesis (SPPS)



5. Mechanism of Peptide Vaccine

5.1 Induction of Immune Response

5.1.1 Factors Affecting T-Cell Stimulation

5.1.2 Factors Affecting B-cell Stimulation

5.1.3 Factors Affecting T-helper Cells

5.2 Delivery System for Peptide Vaccines

5.2.1 Immunostimulatory Adjuvants

5.2.2 Vaccine Delivery System

5.3 Multiple Antigen Peptide System (MAP)

5.3.1 Use of MAP for Foot-and-Mouth Disease



6. Cancer Immunotherapy with Peptide Vaccine

6.1 Peptides as Tumor Antigens

6.2 Immunotherapy with Peptide Vaccination

6.3 Therapeutic Evaluation of Peptide Vaccine

6.3.1 Prostate Cancer

6.3.2 Breast Cancer

6.3.3 Gastric Cancer

6.3.4 Lung Cancer

6.3.5 Pancreatic Cancer



7. Global Peptide Vaccine Market Overview

7.1 Peptide Vaccine – Does have Long & Secure Future?

7.2 Peptide Patents Insights

7.3 Peptide Vaccine Pipeline Overview



8. Global Peptide Vaccine Market Dynamics

8.1 Accelerative Parameters

8.1.1 Peptidomics

8.1.2 Advances in Vaccine Research

8.1.3 Stronger Clinical Pipeline

8.1.4 Emergence of Biologics in Cancer Therapy

8.2 Commercialization Challenges & Modifications

8.2.1 Funding & Legal Issues

8.2.2 Designing & Manufacturing Challenges

8.2.3 Route of Administration

8.2.4 Peptide Pharmacodynamics & Pharmacokinetics



9. Global Peptide Vaccine Market Future Perspectives



10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

10.1 Research

10.2 Preclinical

10.3 Phase-I

10.4 Phase-I/II

10.5 Phase-II

10.6 Phase-III



11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

11.1 No Development Reported

11.2 Discontinued

11.3 Market Withdrawal

11.4 Suspended



12. Competitive Landscape

12.1 AFFiRiS

12.2 AlerGenetica

12.3 Anergis

12.4 Antigen Express

12.5 Apitope Technology

12.6 Araclon Biotech

12.7 Artificial Cell Technologies

12.8 Benovus Bio

12.9 Bionor Pharma

12.10 Circassia

12.11 Celgene Corporation

12.12 Galena Biopharma

12.13 Immatics biotechnologies

12.14 Immune Design

12.15 ImmunoCellular Therapeutics

12.16 Invectys

12.17 ISA Pharmaceuticals

12.18 Lytix Biopharma

12.19 Medinet

12.20 Spotlight Innovation (Memcine Pharmaceuticals)

12.21 Merck Serono

12.22 OncoTherapy Science

12.23 Peptech

12.24 Peptinov

12.25 PeptiVir

12.26 Pharmasyntez

12.27 Renaptys Vaccines

12.28 Sumitomo Dainippon Pharma

12.29 TapImmune

12.30 Targovax

12.31 Vaxon Biotech

Figure 1-1: History of Vaccines

Figure 2-1: Peptides - Amino Acid & Proteins

Figure 2-2: Diversification of Vaccines

Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines

Figure 3-1: Classification of Peptide Vaccine by Source

Figure 3-2: Classification on Basis of Length

Figure 3-3: On the Basis of Epitopes

Figure 4-1: Synthetic Peptide Manufacturing Process

Figure 4-2: Selection of Synthetic Immunogenic Constructs

Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.

Figure 4-4: Fmoc Cleavage

Figure 4-5: Boc Cleavage

Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells

Figure 5-2: Delivery System Pathways by Adjuvants

Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation.

Figure 6-1: TAAs on the Basis of Tissue Distribution

Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells

Figure 6-3: Mechanism of Action of Sipuleucel-T

Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies

Figure 6-5: Peptides Applied in Treating Cancer

Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020

Figure 7-2: Approved Peptide Drugs

Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 7-5: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016

Figure 7-6: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016

Figure 8-1: Global - Peptide Market Favorable Parameters

Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges

Figure 8-3: Routes of Administration

Figure 12-1: Anergis – Clinical Pipeline

Figure 12-2: Apitope Technology – Clinical Pipeline

Figure 12-3: Benovus Bio – Clinical Pipeline

Figure 12-4: Bionor Pharma – Clinical Pipeline

Figure 12-5: Circassia – Clinical Pipeline

Figure 12-6: Celgene - Clinical Pipeline

Figure 12-7: Galena Biopharma - Clinical Pipeline

Figure 12-8: Immatics Biotechnologies - Clinical Pipeline

Figure 12-9: Immune Design – Clinical Pipeline

Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline

Figure 12-11: Invectys – Clinical Pipeline

Figure 12-12: ISA Pharmaceuticals – Clinical Pipeline

Figure 12-13: Lytix Biopharma - Clinical Pipeline

Figure 12-14: Merck Serono – Clinical Pipeline

Figure 12-15: Onco Therapy Science – Clinical Pipeline

Figure 12-16: Peptinov - Clinical Pipeline

Figure 12-17: Sumitomo Dainippon Pharma – Clinical Pipeline

Figure 12-18: Tapimmune – Clinical Pipeline

Figure 12-19: Targovax - Clinical Pipeline

Figure 12-20: Vaxon Biotech - Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.